Elanco Animal Health Incorporated (ELAN) Stock
ELAN Key Statistics
About Elanco Animal Health Incorporated
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
CEO: Jeffrey N. Simmons. Company website
ELAN — Frequently Asked Questions
What is the ELAN stock price today?
Elanco Animal Health Incorporated (ELAN) trades at $22.42, down 1.41% on the day, as of Sep 20, 2026 15:01 UTC.
What is Elanco Animal Health Incorporated's market cap?
Elanco Animal Health Incorporated has a market capitalisation of $11.20B, calculated from the live ELAN share price and shares outstanding.
What is the P/E ratio of ELAN?
ELAN has no meaningful price-to-earnings ratio: Elanco Animal Health Incorporated lost $0.40 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Elanco Animal Health Incorporated make?
Elanco Animal Health Incorporated generated revenue of $5.02B over the trailing twelve months, which puts the stock at 2.23 times sales.
What is the 52-week range for ELAN?
ELAN has traded between $18.22 and $27.98 over the past 52 weeks, and the last price is 19.9% below that high.
Is Elanco Animal Health Incorporated profitable?
No. Elanco Animal Health Incorporated is loss-making, with a net margin of -3.96% over the trailing twelve months.
What is the analyst price target for ELAN?
Wall Street analysts rate ELAN Buy, with an average price target of $28.00, 24.9% above the current price.
What sector is Elanco Animal Health Incorporated in?
Elanco Animal Health Incorporated is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in US.
Who is the CEO of Elanco Animal Health Incorporated?
Jeffrey N. Simmons is the chief executive of Elanco Animal Health Incorporated, which employs 9,650 people.
Where can I track ELAN in real time?
QFI Terminal shows ELAN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ELAN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ELAN in Terminal See plans